To the annoyance of shareholders, shares in Idorsia were down 45% on Friday (Dec. 20) after the company announced delays to a rights deal related to its hypertension drug Tryvio. On November 27, 2024, the Allschwil-based company announced that it had entered exclusive negotiations with an undisclosed party for global rights to aprocitentan, sold under the brand name Tryvio, that resulted in
READ MORELiviniti, a pioneer in pharmacy benefit innovation, announced that LeAnn Boyd, CEO, has been recognized by Modern Healthcare as one of its Women Leaders for 2024. LeAnn is included in an exclusive group of executive women selected for this year’s honor. As CEO and Co-founder of Liviniti, LeAnn has long challenged the pharmacy industry to adopt practices that make prescription drugs more
READ MORE